Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDITUB early bactericidal activity trial in pulmonary tuberculosis
2024-512759-19-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tedizolid and linezolid in pulmonary tuberculosis (TB) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Early bactericidal activity from Day 1 to Day 3. Planned start Aug 2024; status: authorised.
02
Drugs
tedizolidlinezolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2024-512759-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512759-19-00.